Access to brexucabtagene autoleucel for approved lymphoma types
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study provides access to a CAR T-cell therapy (a treatment that uses your own immune cells to fight cancer) for people with certain types of lymphoma who have no other good treatment options. The therapy is available even though it did not meet commercial standards, but it passed safety checks for this study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of the lymphoma types that this therapy is approved for.
- The therapy you have is not commercially released but meets study safety standards.
- You cannot have another leukapheresis (a procedure to collect your blood cells) done.
- Your doctor says you have no other satisfactory treatment options.
- You are medically stable enough to receive the therapy.
- If you are able to have children, you must have a negative pregnancy test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding the targeted therapy pirtobrutinib before CAR T-cell treatment (Tecartus) works better for mantle cell lymphoma that has come back or not responded to other treatments. It aims to improve outcomes for patients who are eligible for CAR T-cell therapy.
This trial studies CAR-T cell therapy, a treatment that uses your own immune cells (T cells) trained to find and attack cancer cells, in people with a type of blood cancer called acute lymphoblastic leukemia (ALL) that has come back or hasn't gone away. The goal is to see how well these therapies work in both children and adults.
This trial tests a new cell therapy called obecabtagene autoleucel (a 'living drug' made from your own immune cells) for people with a type of blood cancer (B-cell ALL) that has responded to initial treatment but may still have tiny traces. The goal is to see if it can prevent relapse after remission.
This trial gives people access to a specially made CAR T-cell therapy (a treatment that uses your own immune cells to fight cancer) that didn't pass the usual quality checks but is still considered safe. It's for patients who have no other good options and are already set to receive this treatment.
This trial tests whether a special immune cell therapy (brexucabtagene autoleucel, or CAR T therapy) can help people with B-cell acute lymphocytic leukemia (ALL) after reducing the number of leukemia cells with a chemo-immunotherapy combination. It is for patients whose cancer has returned or is hard to treat, or for those newly diagnosed with a high-risk form of ALL.
This early-stage trial tests an automated version of axicabtagene ciloleucel (a CAR-T cell therapy) for large B-cell lymphoma that has come back or stopped responding to initial chemotherapy. CAR-T therapy uses your own immune cells, modified in a lab to fight cancer cells.
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.